QLB Biotherapeutics Inc., located in Boston, Massachusetts, is a startup biotechnology company focusing on discovering and developing biological therapeutics. QLB Bio is funded by Qilu Pharmaceutical, and will become its biggest overseas Research and Development Center. QLB Bio is devoted to developing next-generation cancer therapeutics using the transformative potential of immunotherapy. We have an ambitious vision and a growing pipeline of novel cancer immunotherapy biological candidates to treat solid tumors as well as hematologic cancers. To achieve our mission, we seek highly motivated professionals who share our dedication to patients and our passion for discovery, innovation and scientific rigor.
Looking for a particular QLB Biotherapeutics employee's phone or email?
QLB Biotherapeutics Questions
The QLB Biotherapeutics annual revenue was $6.1 million in 2026.
Langzhou Song is the Senior Director, Antibody Discovery, Engineering and Function of QLB Biotherapeutics.
5 people are employed at QLB Biotherapeutics.
QLB Biotherapeutics is based in Boston, Massachusetts.
The NAICS codes for QLB Biotherapeutics are [32541, 3254, 32, 325].
The SIC codes for QLB Biotherapeutics are [283, 28].
Top QLB Biotherapeutics Employees
-
Langzhou Song
Senior Director, Antibody Discovery, Engineering and Function at QLB Biotherapeutics
Cranbury Township, NJ, US15+ -
Yong Pan
Associate Principle Scientist at QLB Biotherapeutics
Lexington, MA, US5+ -
Yiqun Li
Scientist I at QLB Biotherapeutics
Winchester, MA, US12 -
Tian Luo
Scientist II at QLB Biotherapeutics
Guangdong, China -
Rijian Wang
Chief Executive Officer at QLB Biotherapeutics
Mansfield, NJ, US
Related Companies
